Modality
ADC
MOA
MALT1i
Target
MDM2
Pathway
Ferroptosis
BCCRettFL
Development Pipeline
Preclinical
~Mar 2016
→ ~Jun 2017
Phase 1
~Sep 2017
→ ~Dec 2018
Phase 2
Mar 2019
→ Jul 2028
Phase 2Current
NCT08225375
2,427 pts·BCC
2024-12→2027-09·Recruiting
NCT04304684
1,003 pts·Rett
2019-03→2028-07·Active
3,430 total pts2 indications
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2027-09-101.4y awayPh3 Readout· BCC
2028-07-052.3y awayPh3 Readout· Rett
Trial Timeline
2019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3
P2/3
Active
P2/3
Recruit…
Catalysts
Ph3 Readout
2027-09-10 · 1.4y away
BCC
Ph3 Readout
2028-07-05 · 2.3y away
Rett
RecruitingActive|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT08225375 | Phase 2/3 | BCC | Recruiting | 2427 | Biomarker |
| NCT04304684 | Phase 2/3 | Rett | Active | 1003 | PASI75 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| JNJ-2735 | Johnson & Johnson | Phase 2/3 | Cl18.2 | |
| Riboinavolisib | Johnson & Johnson | Phase 2/3 | GLP-1R | |
| LLY-6079 | Eli Lilly | Phase 2 | MDM2 | |
| LLY-3251 | Eli Lilly | Phase 2 | MDM2 | |
| RHH-974 | Roche | Preclinical | JAK1 | |
| NVS-3297 | Novartis | Preclinical | CDK2 | |
| ABB-8985 | AbbVie | Phase 2 | CD20 | |
| GSK-7987 | GSK | Phase 3 | MDM2 | |
| AMG-2752 | Amgen | Preclinical | MDM2 | |
| REG-3155 | Regeneron | Phase 1/2 | MDM2 |